as a part of our planned supply chain robustness initiative , we opened two new plasma collection centers during 2020 , and we now have seven plasma collection centers in various stages of approval and development , including three that are fully operational and collecting plasma . with respect to our fully operational plasma collection centers , two hold fda licenses and the third has a biologics license application ( “ bla ” ) pending an fda decision expected in the fourth quarter of 2021. in addition , one of our fda-approved plasma collection centers also has approvals from the korean ministry of food and drug safety ( “ mfds ” ) , as well as fda approval to implement a hepatitis b immunization program . after giving effect to the progress we made in 2020 with our plasma collection network expansion , we believe we remain on track to achieve our goal of having 10 or more plasma collection centers operating in the u.s. by 2024. a typical plasma collection center , such as those operated by adma biocenters , can collect approximately 30,000 to 50,000 liters of source plasma annually , which may be sold for different prices depending upon the type of plasma , quantity of purchase and market conditions at the time of sale . plasma collected from adma biocenters ' facilities that is not used to manufacture our products or product candidates is sold to third-party customers in the u.s. and in other locations outside the u.s. where we are approved under supply agreements or in the open “ spot ” market . 53 we sell plasma-derived intermediate fractions to certain customers , which are generated as part of our fda-approved manufacturing process for ig and ivig products . in january 2020 , we announced our entry into a five-year manufacturing and supply agreement to produce and sell these intermediate by-products , which are used as the starting raw material to produce other plasma-derived biologics . in addition , from time to time we provide contract manufacturing and testing services for certain third-party clients . we also provide laboratory contracting services to certain customers and anticipate providing contract filling , labeling and packing services upon fda approval and implementation of our in-house fill-finish capabilities through our vanrx sa25 workcell aseptic filling machine . on june 6 , 2017 , we completed the acquisition of certain assets ( the “ biotest assets ” ) of the therapy business unit ( “ btbu ” ) of biotest pharmaceuticals corporation ( “ bpc ” and , together with biotest ag , “ biotest ” ) , which included two fda-licensed products , nabi-hb and bivigam , and an fda-licensed plasma fractionation facility located in boca raton , fl ( the “ boca facility ” ) ( the “ biotest transaction ” ) . our products bivigam bivigam is a plasma-derived ivig that contains a broad range of antibodies similar to those found in normal human plasma . these antibodies are directed against bacteria and viruses and help to protect pi patients against serious infections . bivigam is a purified , sterile , ready-to-use preparation of concentrated human immunoglobulin g antibodies indicated for the treatment of pi , a group of genetic disorders . this includes , but is not limited to , the humoral immune defect in common variable immunodeficiency , x-linked agammaglobulinemia , congenital agammaglobulinemia , wiskott-aldrich syndrome and severe combined immunodeficiency . these pis are a group of genetic disorders . based on recent estimates , these disorders are no longer considered to be very rare , with as many as one in every 1,200 people in the united states having some form of pi . on may 9 , 2019 , the fda approved the prior approval supplement ( the “ pas ” ) for the use of our ivig manufacturing process , thereby enabling us to commence commercial sales of this product in the united states . we resumed production of bivigam during the fourth quarter of 2017 and commercial production is ongoing , using our fda-approved ivig manufacturing process under u.s. department of health and human services ( “ hhs ” ) license no . 2019. we commenced commercial sales for this product in august of 2019. asceniv asceniv is a plasma-derived ivig that contains naturally occurring polyclonal antibodies , which are proteins that are used by the body 's immune system to neutralize microbes , such as bacteria and viruses , and prevent against infection and disease . we manufacture asceniv under hhs license no . 2019 using a process known as fractionation . the centers for medicare and medicaid services ( “ cms ” ) has issued a permanent , product-specific-j-code for asceniv . under the healthcare common procedure coding system ( “ hcpcs ” ) , the j-code ( j1554 ) will become effective april 1 , 2021 and will replace the currently issued c-code for asceniv ( c9072 ) , which can continue to be utilized in the interim for reimbursement purposes . as part of our proprietary manufacturing process for asceniv , we leverage our unique , patented plasma donor screening methodology and tailored plasma pooling design , which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to respiratory syncytial virus ( “ rsv ” ) using our proprietary microneutralization testing assay . we are able to identify the high titer or “ hyperimmune ” plasma that meets our internal and required specifications for asceniv with our patented testing methods and assay . this type of high titer plasma is typically found in less than 10 % of the total donor collection samples we test . story_separator_special_tag impairment of long-lived assets we assess the recoverability of our long-lived assets , which include property and equipment and definite-lived intangible assets , whenever significant events or changes in circumstances indicate impairment may have occurred . if indicators of impairment exist , projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset 's carrying value is recoverable . any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results . for the years ended december 31 , 2020 and 2019 , we determined that there was no impairment of our long-lived assets . goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist . we have the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of the reporting unit associated with the goodwill is less than its carrying amount , including goodwill and other intangible assets . if we conclude that this is the case , then we must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value . an impairment charge is recorded to the extent the reporting unit 's carrying value exceeds its fair value , with the impairment loss recognized not to exceed the total amount of goodwill allocated to that reporting unit . we did not recognize any impairment charges related to goodwill for the years ended december 31 , 2020 and 2019. recent accounting pronouncements in june 2016 , the financial accounting standards board ( the “ fasb ” ) issued accounting standards update ( “ asu ” ) no . 2016-13 , financial instruments – credit losses ( topic 326 ) ( “ asu 2016-13 ” ) , which requires financial assets to be presented at the net amount expected to be collected , with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected . under asu 2016-13 , the entity 's statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets , as well as expected increases or decreases in expected credit losses that have taken place during the period . for public business entities , asu 2016-13 is effective for fiscal years beginning after december 15 , 2019. we adopted asu no . 2016-13 on january 1 , 2020 , and the adoption of this update did not have a significant impact on our consolidated financial statements . 58 in july 2017 , the fasb issued asu no . 2017-11 , earnings per share ( topic 260 ) , distinguishing liabilities from equity ( topic 480 ) , derivatives and hedging ( topic 815 ) ” ( “ asu 2017-11 ” ) . asu 2017-11 changed the classification analysis of certain equity-linked financial instruments ( or embedded features within such instruments ) with down round features . when determining whether certain financial instruments should be classified as liabilities or equity instruments , a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity 's own stock . the amendments also clarify existing disclosure requirements for equity-classified instruments . as a result , a freestanding equity-linked financial instrument ( or embedded conversion option ) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature . for freestanding equity classified financial instruments , the amendments require entities that present earnings per share ( “ eps ” ) in accordance with asc 260 to recognize the effect of the down round feature when it is triggered . that effect is treated as a dividend and as a reduction of income available to common shareholders in basic eps . in addition , convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in asc 470-20 , “ debt—debt with conversion and other options . ” asu 2017-11 became effective for us on january 1 , 2019 , and this update did not have a significant impact on our consolidated financial statements . in february 2016 , the fasb issued asu no . 2016-02 , leases ( topic 842 ) ( “ asu 2016-02 ” ) , which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet . the guidance became effective for fiscal years beginning after december 15 , 2018 , including interim periods within those fiscal years . asu 2016-02 requires modified retrospective adoption for all leases existing at , or entered into after , the date of initial application , with an option to use certain transition relief . we adopted asu 2016-02 on january 1 , 2019 using the option to recognize the cumulative-effect adjustment , if any , as of the date of application , which was also january 1 , 2019. as a result , there was no restatement of comparative periods . we recognized right-to-use assets of approximately $ 1.4 million and corresponding lease liabilities of approximately $ 1.6 million at the date of adoption . we also elected the “ package of practical expedients , ” which permits us to not reassess under the new standard our prior conclusions about lease identification , lease classification and initial direct costs . in addition , we elected the short-term lease recognition exemption for all or embedded leases that qualify . year ended december 31 , 2020 compared to december 31 , 2019 the following table presents a summary of the changes in our results

liquidity and capital resources as of december 31 , 2020 , we had working capital of $ 133.8 million , including cash and cash equivalents of $ 55.9 million , and stockholders ' equity of $ 88.2 million , as compared to working capital of $ 71.8 million , including cash and cash equivalents of $ 26.8 million , and stockholders ' equity of $ 26.2 million as of december 31 , 2019. we have incurred an accumulated deficit of $ 340.5 million since inception , had negative cash flows from operations of $ 102.0 million and $ 76.2 million for the years ended december 31 , 2020 and 2019 , respectively . we have funded our operations over the past few years primarily from the sale of our equity and debt securities . 61 we expect to continue to spend substantial amounts on procurement of raw material plasma and other raw materials necessary to scale up our manufacturing operations , commercial product launches , capacity expansion at the boca facility , building additional plasma collection facilities , product development , quality assurance , regulatory affairs and conducting clinical trials for our product candidates and purchasing clinical trial materials , some of which may be required by the fda . in addition , our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer , requiring substantial investments in raw material plasma and other manufacturing materials . we expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024 and , as a result , we expect that we will need to continue to finance our operations through additional equity or debt financings or through corporate collaboration and licensing arrangements .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources as of december 31 , 2020 , we had working capital of $ 133.8 million , including cash and cash equivalents of $ 55.9 million , and stockholders ' equity of $ 88.2 million , as compared to working capital of $ 71.8 million , including cash and cash equivalents of $ 26.8 million , and stockholders ' equity of $ 26.2 million as of december 31 , 2019. we have incurred an accumulated deficit of $ 340.5 million since inception , had negative cash flows from operations of $ 102.0 million and $ 76.2 million for the years ended december 31 , 2020 and 2019 , respectively . we have funded our operations over the past few years primarily from the sale of our equity and debt securities . 61 we expect to continue to spend substantial amounts on procurement of raw material plasma and other raw materials necessary to scale up our manufacturing operations , commercial product launches , capacity expansion at the boca facility , building additional plasma collection facilities , product development , quality assurance , regulatory affairs and conducting clinical trials for our product candidates and purchasing clinical trial materials , some of which may be required by the fda . in addition , our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer , requiring substantial investments in raw material plasma and other manufacturing materials . we expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024 and , as a result , we expect that we will need to continue to finance our operations through additional equity or debt financings or through corporate collaboration and licensing arrangements .
```    
 Suspicious Activity Report : as a part of our planned supply chain robustness initiative , we opened two new plasma collection centers during 2020 , and we now have seven plasma collection centers in various stages of approval and development , including three that are fully operational and collecting plasma . with respect to our fully operational plasma collection centers , two hold fda licenses and the third has a biologics license application ( “ bla ” ) pending an fda decision expected in the fourth quarter of 2021. in addition , one of our fda-approved plasma collection centers also has approvals from the korean ministry of food and drug safety ( “ mfds ” ) , as well as fda approval to implement a hepatitis b immunization program . after giving effect to the progress we made in 2020 with our plasma collection network expansion , we believe we remain on track to achieve our goal of having 10 or more plasma collection centers operating in the u.s. by 2024. a typical plasma collection center , such as those operated by adma biocenters , can collect approximately 30,000 to 50,000 liters of source plasma annually , which may be sold for different prices depending upon the type of plasma , quantity of purchase and market conditions at the time of sale . plasma collected from adma biocenters ' facilities that is not used to manufacture our products or product candidates is sold to third-party customers in the u.s. and in other locations outside the u.s. where we are approved under supply agreements or in the open “ spot ” market . 53 we sell plasma-derived intermediate fractions to certain customers , which are generated as part of our fda-approved manufacturing process for ig and ivig products . in january 2020 , we announced our entry into a five-year manufacturing and supply agreement to produce and sell these intermediate by-products , which are used as the starting raw material to produce other plasma-derived biologics . in addition , from time to time we provide contract manufacturing and testing services for certain third-party clients . we also provide laboratory contracting services to certain customers and anticipate providing contract filling , labeling and packing services upon fda approval and implementation of our in-house fill-finish capabilities through our vanrx sa25 workcell aseptic filling machine . on june 6 , 2017 , we completed the acquisition of certain assets ( the “ biotest assets ” ) of the therapy business unit ( “ btbu ” ) of biotest pharmaceuticals corporation ( “ bpc ” and , together with biotest ag , “ biotest ” ) , which included two fda-licensed products , nabi-hb and bivigam , and an fda-licensed plasma fractionation facility located in boca raton , fl ( the “ boca facility ” ) ( the “ biotest transaction ” ) . our products bivigam bivigam is a plasma-derived ivig that contains a broad range of antibodies similar to those found in normal human plasma . these antibodies are directed against bacteria and viruses and help to protect pi patients against serious infections . bivigam is a purified , sterile , ready-to-use preparation of concentrated human immunoglobulin g antibodies indicated for the treatment of pi , a group of genetic disorders . this includes , but is not limited to , the humoral immune defect in common variable immunodeficiency , x-linked agammaglobulinemia , congenital agammaglobulinemia , wiskott-aldrich syndrome and severe combined immunodeficiency . these pis are a group of genetic disorders . based on recent estimates , these disorders are no longer considered to be very rare , with as many as one in every 1,200 people in the united states having some form of pi . on may 9 , 2019 , the fda approved the prior approval supplement ( the “ pas ” ) for the use of our ivig manufacturing process , thereby enabling us to commence commercial sales of this product in the united states . we resumed production of bivigam during the fourth quarter of 2017 and commercial production is ongoing , using our fda-approved ivig manufacturing process under u.s. department of health and human services ( “ hhs ” ) license no . 2019. we commenced commercial sales for this product in august of 2019. asceniv asceniv is a plasma-derived ivig that contains naturally occurring polyclonal antibodies , which are proteins that are used by the body 's immune system to neutralize microbes , such as bacteria and viruses , and prevent against infection and disease . we manufacture asceniv under hhs license no . 2019 using a process known as fractionation . the centers for medicare and medicaid services ( “ cms ” ) has issued a permanent , product-specific-j-code for asceniv . under the healthcare common procedure coding system ( “ hcpcs ” ) , the j-code ( j1554 ) will become effective april 1 , 2021 and will replace the currently issued c-code for asceniv ( c9072 ) , which can continue to be utilized in the interim for reimbursement purposes . as part of our proprietary manufacturing process for asceniv , we leverage our unique , patented plasma donor screening methodology and tailored plasma pooling design , which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to respiratory syncytial virus ( “ rsv ” ) using our proprietary microneutralization testing assay . we are able to identify the high titer or “ hyperimmune ” plasma that meets our internal and required specifications for asceniv with our patented testing methods and assay . this type of high titer plasma is typically found in less than 10 % of the total donor collection samples we test . story_separator_special_tag impairment of long-lived assets we assess the recoverability of our long-lived assets , which include property and equipment and definite-lived intangible assets , whenever significant events or changes in circumstances indicate impairment may have occurred . if indicators of impairment exist , projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset 's carrying value is recoverable . any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results . for the years ended december 31 , 2020 and 2019 , we determined that there was no impairment of our long-lived assets . goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist . we have the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of the reporting unit associated with the goodwill is less than its carrying amount , including goodwill and other intangible assets . if we conclude that this is the case , then we must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value . an impairment charge is recorded to the extent the reporting unit 's carrying value exceeds its fair value , with the impairment loss recognized not to exceed the total amount of goodwill allocated to that reporting unit . we did not recognize any impairment charges related to goodwill for the years ended december 31 , 2020 and 2019. recent accounting pronouncements in june 2016 , the financial accounting standards board ( the “ fasb ” ) issued accounting standards update ( “ asu ” ) no . 2016-13 , financial instruments – credit losses ( topic 326 ) ( “ asu 2016-13 ” ) , which requires financial assets to be presented at the net amount expected to be collected , with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected . under asu 2016-13 , the entity 's statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets , as well as expected increases or decreases in expected credit losses that have taken place during the period . for public business entities , asu 2016-13 is effective for fiscal years beginning after december 15 , 2019. we adopted asu no . 2016-13 on january 1 , 2020 , and the adoption of this update did not have a significant impact on our consolidated financial statements . 58 in july 2017 , the fasb issued asu no . 2017-11 , earnings per share ( topic 260 ) , distinguishing liabilities from equity ( topic 480 ) , derivatives and hedging ( topic 815 ) ” ( “ asu 2017-11 ” ) . asu 2017-11 changed the classification analysis of certain equity-linked financial instruments ( or embedded features within such instruments ) with down round features . when determining whether certain financial instruments should be classified as liabilities or equity instruments , a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity 's own stock . the amendments also clarify existing disclosure requirements for equity-classified instruments . as a result , a freestanding equity-linked financial instrument ( or embedded conversion option ) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature . for freestanding equity classified financial instruments , the amendments require entities that present earnings per share ( “ eps ” ) in accordance with asc 260 to recognize the effect of the down round feature when it is triggered . that effect is treated as a dividend and as a reduction of income available to common shareholders in basic eps . in addition , convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in asc 470-20 , “ debt—debt with conversion and other options . ” asu 2017-11 became effective for us on january 1 , 2019 , and this update did not have a significant impact on our consolidated financial statements . in february 2016 , the fasb issued asu no . 2016-02 , leases ( topic 842 ) ( “ asu 2016-02 ” ) , which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet . the guidance became effective for fiscal years beginning after december 15 , 2018 , including interim periods within those fiscal years . asu 2016-02 requires modified retrospective adoption for all leases existing at , or entered into after , the date of initial application , with an option to use certain transition relief . we adopted asu 2016-02 on january 1 , 2019 using the option to recognize the cumulative-effect adjustment , if any , as of the date of application , which was also january 1 , 2019. as a result , there was no restatement of comparative periods . we recognized right-to-use assets of approximately $ 1.4 million and corresponding lease liabilities of approximately $ 1.6 million at the date of adoption . we also elected the “ package of practical expedients , ” which permits us to not reassess under the new standard our prior conclusions about lease identification , lease classification and initial direct costs . in addition , we elected the short-term lease recognition exemption for all or embedded leases that qualify . year ended december 31 , 2020 compared to december 31 , 2019 the following table presents a summary of the changes in our results

